CNTX: Context Therapeutics Inc Company Value to Net Income

Financial quote visualization on GURU.Markets demonstrates the performance of Context Therapeutics (CNTX), whose model relies on external protein synthesis and third-party clinical tests, with the metric standing at -0.40. The business focuses on developing targeted drugs against ovarian and breast tumors. The company's capitalization is determined exclusively by the success of new molecule trials evolving within a specific medical cycle.

Price to Earnings Ratio: Context Therapeutics Inc (CNTX) for 07/04/2022 - 11/14/2026

Comprehensive metric breakdowns and analytics for Context Therapeutics Inc (CNTX)

- share price and expert price forecast:

Price Performance Chart Context Tx|CNTX - Consensus Target

- market capitalization information:

Market Value Context Therapeutics Inc.|CNTX - Real Price to Acquire Entire Company

- balance sheet net asset value indicators:

Accounting Value per Share Context Therapeutics|CNTX - Company Book Value|Market-to-Book Ratio contexttherapeutics.com|CNTX - Aggregate Company Assets

- debt obligations and liquidity statistics:

- company profitability and valuation multiples indicators:

CNTX - Company Net Income|Net Profit Forecast Context Therapeutics|CNTX - Price to Earnings Ratio|Market Cap to Future Earnings Ratio Context Tx|CNTX - PEG Multiple|Company Value to EBITDA Context Therapeutics Inc.|CNTX - Operating profit before deduction of amortization|Earnings per share for the last 12 months Context Therapeutics|CNTX - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months contexttherapeutics.com|CNTX - Net earnings per share growth this year|Expected earnings per share trend next year Context Therapeutics

- sales volume and revenue indicators:

CNTX - Company Sales|Company Projected Revenue Volume Context Tx|CNTX - P/S Multiple|Forward Price to Sales Context Therapeutics Inc.

Comprehensive company analysis:contexttherapeutics.com CNTX

Signature product of Context Therapeutics Inc.

The P/E ratio reflects the market value of a single unit of profit, allowing for the determination of whether an asset is overvalued or possesses potential undervaluation relative to growth rates. By analyzing the P/E based on company financial statements, an investor assesses the capitalization of Context Therapeutics (CNTX) through the lens of its unique selective inhibitors, which confirms the fundamental stability of the business within the targeted oncology therapy segment.

Key competitors